AI-driven breakthrough targets gut repair in IBD
Genetic Engineering & Biotechnology News (GEN) - 11-Dec-2024How Insilico Medicine’s innovative drug ISM5411 could transform inflammatory bowel disease treatment
Join the club for FREE to access the whole archive and other member benefits.
Senior Business Editor and reporter specializing in biopharma business news and industry issues at GEN
Alex Philippidis specializes in biopharma business news and industry issues as Senior Business Editor for GEN / Genetic Engineering & Biotechnology News, and its parent company, Mary Ann Liebert, Inc.
Alex joined GEN in 2011 after four years at GenomeWeb L.L.C., where he covered research institutes and spent three years following biotech economic development as editor of the weekly newsletter BioRegion News.
Previously, Alex worked more than 20 years for various newspapers covering business, science, Navy, and general-interest news, including the Westchester County Business Journal, where he served as Editor-in-Chief and held reporting positions from 1994 to 2007. Alex reported for Soundings, an independent newspaper covering the U.S. Navy and Marine Corps in Norfolk, VA, from 1992-1993; and reported for Gannett Suburban Newspapers (now The Journal News) in White Plains, NY, from 1987-1992.
He has been interviewed and quoted by news outlets that include The New York Times, the BBC, WCBS-TV (CBS2 New York), Triad Business Journal, and WHYY-FM, the NPR station serving the Philadelphia region. Alex has delivered presentations before the Association of University Research Parks, the BioHealth Capital Region, Builds Bio+, California Biomanufacturing Center, and Roundtable Japan.
Visit website: https://www.genengnews.com/contributors/
See also
News provider in the fields of biotechnology and genetic engineering
Details last updated 29-Jul-2023
How Insilico Medicine’s innovative drug ISM5411 could transform inflammatory bowel disease treatment
Tome Biosciences secures $213m to advance next-gen gene editing
Could target the treatment of a broader range of fibrotic indications beyond idiopathic pulmonary fibrosis